化合物 T13913 T13913

Product Introduction
Bioactivity


英文名: TAK-778

描述: TAK-778, a derivative of ipriflavone, demonstrates the ability to stimulate bone growth in both in vitro and in vivo models.

体外活性: In vitro and in vivo models, TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth. Continuous treatment with TAK-778 (10 μM) for 1 to 21 days results in an increase in the area of mineralized nodules. TAK-778 at concentrations of 1 μM and higher significantly stimulates the activity of cellular Alkaline phosphatase (ALP). TAK-778 increases slightly but significantly the DNA content of the cells at the confluence stage. Treatment with TAK-778 also results in dose-dependent increases in the amount of soluble collagen and osteocalcin secreted into culture medium from days 5 to 7. the secretion of both TGF-β and IGF-I at every time point during the 21 days of culture enhanced by TAK-778. Treatment of the cells with TAK-778 does not induce ALP activity, but does result in a dose-dependent increase in the saturated cell density. TAK-778(10 μM) significantly reduces the saturated cell density[2].

体内活性: TAK-778/PLGA-MC (a single local application,0.2 to 5 mg/site) results in a dose-dependent increase in the radio-opaque area formed in the defect. Histological studies show the defect area is occupied by a bony bridge and the newly-formed radio-opaque area corresponds to a calcified bone containing bone marrow cavities surrounded by thick osteoid seams with cuboidal osteoblasts. Two months after the operation, the TAK-778/PLGA-MC pellets induce radiological osseous union across the defects[2]. TAK-778 (Oral treatment of OVX rats)causes a more pronounced increase in bone mineral density (BMD) of the lumbar vertebrae compare to vehicle controls[3].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: TAK 778 | TAK-778 | TAK778

化合物 T13913 T13913信息由TargetMol中国为您提供，如您想了解更多关于化合物 T13913 T13913报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途